CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 218-220
DOI: 10.4103/ijmpo.ijmpo_246_19
Drug Review

Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Sandip Ganguly
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Joydeep Ghosh
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Bivas Biswas
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Deepak Dabkara
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
› Author Affiliations
Financial support and sponsorship Nil.

Abstract

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises around 20%–25% of breast cancers. With the discovery of trastuzumab, there was a marked improvement in the survival of patients with HER2-positive breast cancer both in curative and metastatic settings. However, patients with trastuzumab will eventually progress or develop recurrences. Newer anti-HER2 therapies have evolved to improve the outcome of this group of patients. One of them is monoclonal antibody–drug conjugate which is ado-trastuzumab emtansine.



Publication History

Received: 05 December 2019

Accepted: 13 February 2020

Article published online:
23 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest 2010; 28: 963-8
  • 2 Adjuvant Trastuzumab in HER2-Positive Breast Cancer. NEJM. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa0910383. [Last accessed on 2019 Nov 30].
  • 3 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
  • 4 Barok M, Joensuu H, Isola J. Trastuzumab emtansine: Mechanisms of action and drug resistance. Breast Cancer Res 2014; 16: 209
  • 5 Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91
  • 6 Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 732-42
  • 7 Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 2017; 18: 743-54
  • 8 Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M. et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689-99
  • 9 Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study. J Clin Oncol 2017; 35: 141-8
  • 10 Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE. Cancer 2019; 125: 3974-84
  • 11 von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-28
  • 12 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf. [Last accessed on 2019 Dec 03]